Maple Tree Capital released its Q3 2025 investor letter, showing mixed results. The Jonagold portfolio had a 13.12% loss due to Upstart’s decline, while the Heartwood portfolio gained 40.2%, surpassing the S&P 500. Hims & Hers Health, Inc. (NYSE:HIMS) saw a -6.09% one-month return and closed at $34.10 per share on December 29, 2025.

In its investor letter, Maple Tree Capital discussed selling its position in Hims & Hers Health, Inc. (NYSE:HIMS) due to increased regulatory risks. HIMS stock closed at $34.10 per share on December 29, 2025, with a market capitalization of $7.763 billion. The firm reallocated into Upstart and remains optimistic about long-term performance.

Hims & Hers Health, Inc. (NYSE:HIMS) reported a 49% year-over-year revenue increase in Q3 2025, reaching nearly $600 million. The company’s adjusted EBITDA margins exceeded 13%. While acknowledging HIMS’ potential, Maple Tree Capital sees greater upside potential in certain AI stocks. HIMS is not among the 30 most popular stocks among hedge funds.

Read more at Yahoo Finance: Hims & Hers Health (HIMS) Fell Due to Increased Regulatory Challenges